en
Font:
Аа Аа Аа
Color::
Аа Аа Аа
B/W images:
B/W - B/W +
Normal version

“InterChem” started the production of the drug AMISPIRON IC

09.12.2014

The drug is used in acute and chronic inflammation of the respiratory tract and ENT (otitis media, sinusitis, rhinitis, nasopharyngitis). AMISPIRON IC has anti-inflammatory properties and has antispasmodic effect on the smooth muscles of the bronchi. Also, the drug is used in the complex treatment of bronchial asthma, with seasonal and perennial allergic rhinitis and other allergic manifestations of the respiratory system and otolaryngology. AMISPIRON IC is used in the presence of respiratory symptoms of measles, influenza and for the symptomatic treatment of whooping cough. It is produced in the form of prolonged action tablets coated with a film coating. One tablet contains 80 mg of fenspiride hydrochloride.

Recent publications

InterChem Among the Top 13 Best Educational Projects in Ukraine

InterChem Among the Top 13 Best Educational Projects in Ukraine

InterChem has been recognized among the Top 13 Best Educational Projects initiated by Ukrainian businesses. Within the national project “Investing in Education”, the ...

Read more
InterChem at URC 2025: Signing of the Ukraine–EU Memorandum on Critical Medicines

InterChem at URC 2025: Signing of the Ukraine–EU Memorandum on Critical Medicines

Anatoliy Reder, CEO of InterChem and official representative of the Association of Ukrainian Medicines Manufacturers (AULM), signed a Memorandum of Cooperation between Ukraine ...

Read more
Anatoliy Reder, CEO of InterChem, ranked among Ukraine’s Top 50 CEOs

Anatoliy Reder, CEO of InterChem, ranked among Ukraine’s Top 50 CEOs

Anatoliy Reder became the winner in the nomination “Leader in Pharmaceutical Research and Innovation” in Ukraine’s national Top 50 CEOs ranking. The list ...

Read more
Anatoliy Reder, CEO of InterChem: “We are Ukrainians. We do not work with the enemy.”

Anatoliy Reder, CEO of InterChem: “We are Ukrainians. We do not work with the enemy.”

According to research by Gradus Research and Deloitte, about 70% of Ukrainians have a negative attitude toward brands that continue operating in Russia. ...

Read more